Literature DB >> 26048873

Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.

Christian R Engwerda1, Greg Matlashewski2.   

Abstract

A visceral leishmaniasis (VL) elimination target set for the Indian subcontinent in 2005 is being met in many endemic areas without a vaccine. This begs a question: is a VL vaccine needed if elimination targets can be met with current control programs? Here, we argue that a vaccine will be critical if the success of recent VL control efforts are to be sustained. However, not only do we require a safe and effective vaccine, but we also need to know how this should be used for maximum impact. In particular, identifying appropriate target populations to vaccinate will be crucial.
© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26048873     DOI: 10.1093/trstmh/trv039

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  12 in total

1.  A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.

Authors:  Nahid Mortazavidehkordi; Ali Fallah; Abbas Abdollahi; Vahid Kia; Hossein Khanahmad; Zahra Ghayour Najafabadi; Nooshin Hashemi; Bahareh Estiri; Zahra Roudbari; Ali Najafi; Akbar Farjadfar; Seyed Hossein Hejazi
Journal:  Parasitol Res       Date:  2018-05-29       Impact factor: 2.289

Review 2.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

3.  In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors.

Authors:  Felipe Rodriguez; Sarah F John; Eva Iniguez; Sebastian Montalvo; Karina Michael; Lyndsey White; Dong Liang; Omonike A Olaleye; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

4.  HisAK70: progress towards a vaccine against different forms of leishmaniosis.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; José A Ruiz-Santa-Quiteria; Ricardo De La Fuente; Lara Ordóñez-Gutiérrez; Abel Martínez-Rodrigo; Alicia Mas; Javier Carrión
Journal:  Parasit Vectors       Date:  2015-12-09       Impact factor: 3.876

5.  A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.

Authors:  Mohamed Osman; Anoop Mistry; Ada Keding; Rhian Gabe; Elizabeth Cook; Sarah Forrester; Rebecca Wiggins; Stefania Di Marco; Stefano Colloca; Loredana Siani; Riccardo Cortese; Deborah F Smith; Toni Aebischer; Paul M Kaye; Charles J Lacey
Journal:  PLoS Negl Trop Dis       Date:  2017-05-12

6.  Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani.

Authors:  Sumit Joshi; Narendra Kumar Yadav; Keerti Rawat; Vikash Kumar; Rafat Ali; Amogh Anant Sahasrabuddhe; Mohammad Imran Siddiqi; Wahajul Haq; Shyam Sundar; Anuradha Dube
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

7.  miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen -/- Immunization.

Authors:  Sreenivas Gannavaram; Parna Bhattacharya; Abid Siddiqui; Nevien Ismail; Subha Madhavan; Hira L Nakhasi
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

8.  Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.

Authors:  Sumit Joshi; Narendra K Yadav; Keerti Rawat; Chandra Dev P Tripathi; Anil K Jaiswal; Prashant Khare; Rati Tandon; Rajendra K Baharia; Sanchita Das; Reema Gupta; Pramod K Kushawaha; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  Front Microbiol       Date:  2016-03-22       Impact factor: 5.640

Review 9.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

10.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.